Breakthrough Discovery: Scientists Uncover the Root Cause of Preeclampsia & a Promising Way to Treat It
Preeclampsia is a serious and potentially life-threatening pregnancy complication that affects millions of women worldwide. It is estimated to impact nearly 1 in 10 pregnancies globally, and about 5% to 8% of pregnancies in the United States. Despite being so common, doctors and scientists have struggled for decades to fully understand what causes this condition.
Now, in a major scientific breakthrough, researchers may have finally found the root cause—and more importantly, a way to potentially treat it.
What Is Preeclampsia and Why Is It Dangerous?
Preeclampsia is a condition that usually develops after the 20th week of pregnancy. It is mainly characterized by high blood pressure and damage to organs such as the liver and kidneys. If not treated in time, it can lead to severe complications for both the mother and the baby.
For mothers, preeclampsia increases the risk of long-term health issues such as heart disease, stroke, kidney disease, and even dementia later in life. For babies, it can lead to premature birth, low birth weight, and in severe cases, infant mortality.
Because its symptoms can overlap with other conditions, diagnosing preeclampsia early has always been a challenge.
The Breakthrough Discovery
A team of researchers led by Johann Gudjonsson and Olesya Plazyo has identified a key molecular factor that may be responsible for triggering preeclampsia.
Their research, published in Circulation, points to a gene called VGLL3 as a central driver of the disease.
Using advanced techniques like single-cell and spatial RNA sequencing, the team studied human placental tissue in great detail. They discovered that the VGLL3 gene is significantly more active in placentas affected by preeclampsia.
How VGLL3 Causes Preeclampsia
VGLL3 plays an important role in regulating gene activity in the body. However, when its levels become too high, it starts to disrupt several key processes in the placenta:
Abnormal immune activation: The body’s immune system becomes overly active, leading to inflammation.
Poor placental development: Cells responsible for forming the placenta (trophoblasts) do not develop properly.
Blood vessel dysfunction: Blood flow between mother and baby is affected.
These problems together lead to the classic symptoms of preeclampsia—high blood pressure, restricted fetal growth, and increased health risks.
In simple terms, VGLL3 acts like a “volume knob” for multiple harmful processes. When turned up too high, it amplifies the disease.
From Skin Research to Pregnancy Science
Interestingly, this discovery did not begin with pregnancy research at all.
Years ago, scientists studying skin diseases noticed that VGLL3 was more active in women than in men. It was also linked to autoimmune diseases like lupus and systemic sclerosis—conditions that are more common in women and are known to increase the risk of preeclampsia.
This unexpected connection led researchers to investigate whether VGLL3 might also play a role during pregnancy.
A casual conversation between researchers from different fields helped spark this idea, showing how important collaboration is in scientific discovery.
Testing the Theory: Mice and Human Studies
To confirm their findings, the researchers conducted experiments in both animal models and human tissue.
In Mice:
When VGLL3 levels were increased, pregnant mice developed high blood pressure—similar to preeclampsia.
When the gene was removed, pregnancies remained completely normal.
In Human Placental Tissue:
Scientists reduced VGLL3 activity in samples from patients with preeclampsia.
As a result, many harmful features of the disease were reversed or improved.
This consistency across different models strongly supports the idea that VGLL3 is a key driver of preeclampsia.
Why This Discovery Is So Important
One of the most exciting parts of this research is that VGLL3 does not appear to be essential for a healthy pregnancy.
This is critical because many previously studied genes, like FLT1, are necessary for normal placental development. Blocking them can harm both the mother and the baby.
VGLL3, however, seems different. It acts more like a “disease amplifier” rather than a necessary component. This means it could potentially be targeted safely without interfering with normal pregnancy.
Connecting the Dots: A Unified Explanation
For years, scientists believed that preeclampsia was not a single disease but a collection of different problems. Some cases showed blood vessel issues, others showed inflammation, and some showed tissue damage.
This new research suggests that VGLL3 may be the missing link connecting all these features.
It influences:
Blood vessel formation (angiogenesis)
Immune system activity
Cell growth and differentiation
Tissue structure and fibrosis
In other words, VGLL3 may unify multiple pathways into one central mechanism.
What Could This Mean for Future Treatments?
Currently, the only definitive treatment for preeclampsia is delivery of the baby, which is not always safe—especially if it happens too early.
This new discovery opens the door to entirely new treatment strategies.
Researchers are now exploring ways to:
Develop drugs that reduce VGLL3 activity
Target related signaling pathways (like the Hippo pathway)
Create early diagnostic tools based on VGLL3 levels
If successful, these approaches could:
Prevent preeclampsia before it becomes severe
Extend pregnancy safely
Improve outcomes for both mothers and babies
A Step Toward Safer Pregnancies
This breakthrough represents a major step forward in understanding one of pregnancy’s most dangerous complications.
By identifying VGLL3 as a central driver, scientists have moved beyond simply observing symptoms to understanding the actual mechanism behind the disease.
As research continues, this discovery could lead to life-saving treatments and better care for millions of women around the world.
Final Thoughts
Science often progresses through unexpected connections—and this discovery is a perfect example. What began as research into skin biology has now provided a potential solution to a long-standing medical mystery.
While more studies are needed before treatments become widely available, the findings offer real hope. For the first time, we may be close to not just managing preeclampsia—but preventing it altogether.
And that could change the future of pregnancy care forever.
Reference: Olesya Plazyo et al, Defective Trophoblast Differentiation, Endothelial Dysfunction, and Immune Dysregulation in Preeclampsia Coalesce on a Placental VGLL3-Centered Gene Network, Circulation (2026). DOI: 10.1161/circulationaha.125.076218

Comments
Post a Comment